Vagus Nerve Stimulation for Stroke Recovery
Upper limb motor impairment remains one of the most disabling consequences of stroke, with fewer than 20% of patients achieving full arm recovery. Despite intensive rehabilitation, many patients plateau in their recovery within the first few months. Vagus nerve stimulation (VNS) paired with rehabilitation has emerged as a promising neuromodulation strategy to enhance motor recovery in chronic stroke. Implanted cervical VNS (Vivistim system) is currently the only FDA-approved VNS approach for stroke rehabilitation (approved 2021); non-invasive alternatives such as transcutaneous auricular VNS (ta-VNS) remain investigational.
🔹 Bottom Line: VNS for Stroke Recovery
- FDA-approved: Only implanted cervical VNS (Vivistim) is FDA-approved for stroke rehabilitation; ta-VNS and other non-invasive approaches remain investigational.
- Mechanism: VNS paired with movement releases acetylcholine and norepinephrine, enhancing synaptic plasticity during task-specific rehabilitation.
- VNS-REHAB trial: Implanted VNS + rehab improved upper limb function (FMA-UE +5.0 vs +2.4 points, p=0.001) with 47% achieving clinically meaningful response vs 24% with sham.
- Durability: Gains are sustained at 1 year, with 72% of responders maintaining or improving function.
- Patient selection: Chronic ischemic stroke (≥9 months), moderate-to-severe arm weakness (FMA-UE 20–40), some residual voluntary movement.
Mechanism of Action
The rationale for VNS in stroke recovery is based on the principle of targeted plasticity. The vagus nerve projects to the nucleus tractus solitarius, which has widespread connections to neuromodulatory centers including the locus coeruleus (norepinephrine) and basal forebrain (acetylcholine). When VNS is delivered precisely during motor training, these neuromodulators are released, enhancing long-term potentiation and cortical map reorganization in circuits activated by the paired movement.
Preclinical studies demonstrated that VNS paired with specific motor tasks—but not unpaired stimulation—drives significant reorganization of motor cortex representations and improves skilled motor function after experimental stroke.
Types of VNS Approaches
| Approach | Device | Target | Invasiveness | FDA Status |
|---|---|---|---|---|
| Implanted cervical VNS | Vivistim (MicroTransponder) | Left cervical vagus nerve | Surgical implant | FDA approved (2021) |
| Transcutaneous auricular VNS (ta-VNS) | External ear clip device | Auricular branch of vagus (cymba conchae) | Non-invasive | Investigational |
| Non-invasive cervical VNS (nVNS) | GammaCore | Transcutaneous cervical | Non-invasive | Investigational for stroke |
Key Trials
VNS-REHAB — Pivotal Trial
The VNS-REHAB trial was the landmark study that led to FDA approval of the Vivistim system for chronic stroke rehabilitation.
- Design: Randomized, triple-blind, sham-controlled trial
- Population: 108 patients with chronic ischemic stroke (9 months to 10 years post-stroke) and moderate-to-severe upper limb impairment (FMA-UE 20–50)
- Intervention: Implanted VNS paired with task-specific rehabilitation vs sham stimulation with identical rehab; 6 weeks in-clinic therapy followed by home-based therapy
- Primary outcome: Change in Fugl-Meyer Assessment Upper Extremity (FMA-UE) score
🔹 VNS-REHAB Results
- FMA-UE improvement: +5.0 points (VNS) vs +2.4 points (sham), p = 0.001
- Clinically meaningful response (≥6-point gain): 47% (VNS) vs 24% (sham), OR 2.67, p = 0.01
- Safety: No serious device-related adverse events
- Durability: Gains sustained at 90-day follow-up
VNS-REHAB 1-Year Outcomes (2025)
The VNS-REHAB 1-Year follow-up demonstrated the durability of VNS-paired rehabilitation.
- Long-term efficacy: Mean FMA-UE improvement increased to +6.6 points at 1 year (vs +5.0 at 90 days)
- Sustained response: 72% of initial responders (≥6-point gain at 90 days) maintained or improved their gains
- Crossover results: 45 sham patients who crossed over to active VNS showed similar improvements to the original VNS group
- Safety: No long-term adverse effects related to VNS
ta-VNS for Acute Stroke (2022)
The ta-VNS for acute stroke trial evaluated non-invasive transcutaneous auricular VNS in the acute/subacute setting.
- Design: Double-blind, randomized, sham-controlled trial
- Population: 60 patients with acute stroke (ischemic or hemorrhagic) within 1 month of onset
- Intervention: 4 weeks of rehabilitation paired with active ta-VNS or sham stimulation
- Results: Significantly greater improvements in motor function, sensory function, emotional state, and quality of life with ta-VNS, sustained at 1-year follow-up
- Safety: Well-tolerated with no major adverse effects
- Status: Promising but not FDA-approved; requires further validation
🔹 Clinical Relevance: Implanted vs Non-Invasive VNS
- Implanted VNS (Vivistim): Only FDA-approved option for chronic stroke; requires surgical implantation but allows precise, consistent stimulation paired with movements
- ta-VNS: Non-invasive alternative; promising early data in acute stroke but not yet FDA-approved for this indication; stimulation parameters and protocols still being optimized
- Key principle: Both approaches rely on pairing stimulation with task-specific rehabilitation—VNS alone without rehab is not effective
Patient Selection
Based on the VNS-REHAB trial inclusion criteria and clinical experience, ideal candidates for implanted VNS include:
| Criterion | Requirement | Rationale |
|---|---|---|
| Time since stroke | ≥9 months (up to 10 years studied) | Chronic phase; plateau in spontaneous recovery |
| Stroke type | Ischemic | Hemorrhagic stroke excluded from pivotal trial |
| Upper limb impairment | FMA-UE 20–40 | Moderate-to-severe; some residual movement required |
| Voluntary movement | Some preserved ability to initiate arm/hand movement | Necessary for task-specific pairing |
| Motivation | Committed to intensive rehabilitation program | 6 weeks in-clinic + ongoing home therapy |
| Cognition | Able to follow commands and participate in therapy | Active engagement required |
🔴 Contraindications and Cautions
- Active implantable devices (pacemaker, defibrillator) — relative contraindication
- Prior left cervical vagotomy
- Severe spasticity limiting movement (may need botulinum toxin first)
- Complete flaccid paralysis (no residual motor function)
- Uncontrolled seizures
- Significant cognitive impairment precluding participation in therapy
🔹 Practical Workflow: VNS for Stroke Rehabilitation
Step 1: Referral & OT Evaluation
- Patient referred to certified VNS rehabilitation center
- Occupational therapist (OT) performs baseline assessment
- Fugl-Meyer Upper Extremity (FMA-UE) score determined — target range: 20–40
- Confirm patient has some voluntary arm/hand movement and is motivated for intensive therapy
Step 2: Surgical Implantation
- Neurosurgeon implants VNS lead around left cervical vagus nerve
- Pulse generator placed subcutaneously in left chest (similar to pacemaker)
- Outpatient procedure; ~1–2 week recovery before starting therapy
Step 3: In-Clinic Rehabilitation (6 weeks)
- 18 sessions (3×/week) of task-specific upper limb therapy with OT
- VNS paired with each successful movement (~300–400 stimulations/session)
- Therapist controls stimulation timing via wireless device
Step 4: Home-Based Therapy (ongoing)
- Patient receives portable stimulation device for home use
- Daily home exercises (30–60 min) with self-administered VNS pairing
- Periodic OT follow-up visits to progress exercises and monitor gains
- Long-term maintenance: continued home practice to sustain improvements
Other Neuromodulation Approaches for Stroke Recovery
While VNS has the strongest evidence base, other neuromodulation strategies are under investigation:
Deep Brain Stimulation — EDEN trial
The EDEN trial evaluated deep brain stimulation (DBS) of the cerebellar dentate nucleus paired with rehabilitation in chronic post-stroke hemiparesis (1–3 years post-stroke).
- Results: Safe and feasible; median FMA-UE improvement of +7 points overall, +15 points in patients with preserved distal motor function
- Mechanism: Cerebellar DBS may enhance motor cortex excitability and promote cortical reorganization
- Status: Early-phase; further trials needed
Spinal Cord Stimulation — SCS Trial
The SCS for Post-Stroke Hemiparesis study evaluated cervical epidural spinal cord stimulation in chronic stroke.
- Results: Immediate +32% strength increase with stimulation ON; mean +6.6 FMA-UE points; 3/7 patients with residual corticospinal connectivity regained hand/finger function
- Status: Early feasibility data; larger trials needed
Trial Comparison Table
| Trial | Year | VNS Type | Population | N | ΔFMA-UE | Response Rate |
|---|---|---|---|---|---|---|
| VNS-REHAB | 2021 | Implanted cervical | Chronic (9 mo–10 yr) | 108 | +5.0 vs +2.4 | 47% vs 24% |
| VNS-REHAB 1-Year | 2025 | Implanted cervical | Chronic (follow-up) | 108 | +6.6 at 1 year | 72% sustained |
| ta-VNS Acute Stroke | 2022 | Transcutaneous auricular | Acute (<1 month) | 60 | Significant benefit | Sustained at 1 year |
| EDEN (DBS) | 2023 | Cerebellar DBS | Chronic (1–3 yr) | 12 | +7 (median) | +15 in responders |
| SCS Hemiparesis | 2025 | Cervical epidural SCS | Chronic (>6 mo) | 7 | +6.6 | +32% strength |
Conclusion
Vagus nerve stimulation paired with rehabilitation represents a significant advance in chronic stroke recovery, offering hope to patients who have plateaued with conventional therapy. Implanted cervical VNS (Vivistim) is the only FDA-approved neuromodulation approach for stroke rehabilitation, with the VNS-REHAB trial demonstrating meaningful and durable improvements in upper limb function. Non-invasive approaches like ta-VNS are promising alternatives that may expand access in the future, particularly in the acute/subacute phase, but remain investigational. As with all neuromodulation strategies, the key to success is pairing stimulation with intensive, task-specific rehabilitation—the stimulation enhances plasticity, but the rehabilitation provides the substrate for motor learning.
References
- Dawson J, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet. 2021;397(10284):1545–1553.
- Dawson J, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor impairment and function after chronic ischemic stroke: subgroup analysis of the randomized, blinded, pivotal, VNS-REHAB device trial. Neurorehabil Neural Repair. 2023;37(6):367–373.
- Wu D, et al. Long-term outcomes of transcutaneous auricular vagus nerve stimulation paired with rehabilitation in acute stroke. Front Neurol. 2022;13:1–12.
- Engineer ND, et al. Targeted vagus nerve stimulation for rehabilitation after stroke. Front Neurosci. 2019;13:280.
- Pruitt DT, et al. Vagus nerve stimulation delivered with motor training enhances recovery of function after traumatic brain injury. J Neurotrauma. 2016;33(9):871–879.
- Kimberley TJ, et al. Vagus nerve stimulation paired with upper limb rehabilitation after chronic stroke: a blinded randomized pilot study. Stroke. 2018;49(11):2789–2792.